Switch theme
Sign up to access all valuation multiples
Anhui Huaren Health Pharmaceutical Co Ltd focuses on the pharmaceutical retail industry and forms a retail chain, retail centralized procurement, retail service, and retail e-commerce system.
2001
6K+
Last FY Revenue $629M
Last FY EBITDA $71.1M
$688M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Anhui Huaren Health achieved revenue of $629M and an EBITDA of $71.1M.
Anhui Huaren Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Anhui Huaren Health valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $629M | XXX | XXX | XXX |
| Gross Profit | XXX | $205M | XXX | XXX | XXX |
| Gross Margin | XXX | 33% | XXX | XXX | XXX |
| EBITDA | XXX | $71.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 11% | XXX | XXX | XXX |
| EBIT | XXX | $35.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | 6% | XXX | XXX | XXX |
| Net Profit | XXX | $19.1M | XXX | XXX | XXX |
| Net Margin | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Anhui Huaren Health's stock price is CNY 12 (or $2).
Anhui Huaren Health has current market cap of CNY 4.9B (or $673M), and EV of CNY 5.0B (or $688M).
See Anhui Huaren Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $688M | $673M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Anhui Huaren Health has market cap of $673M and EV of $688M.
Anhui Huaren Health's trades at 1.1x EV/Revenue multiple, and 9.7x EV/EBITDA.
Equity research analysts estimate Anhui Huaren Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Anhui Huaren Health's P/E ratio is not available.
See valuation multiples for Anhui Huaren Health and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $673M | XXX | $673M | XXX | XXX | XXX |
| EV (current) | $688M | XXX | $688M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 9.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 19.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 35.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 12.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAnhui Huaren Health's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $28K for the same period.
Anhui Huaren Health's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Anhui Huaren Health's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Anhui Huaren Health and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $28K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anhui Huaren Health acquired XXX companies to date.
Last acquisition by Anhui Huaren Health was XXXXXXXX, XXXXX XXXXX XXXXXX . Anhui Huaren Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Anhui Huaren Health founded? | Anhui Huaren Health was founded in 2001. |
| Where is Anhui Huaren Health headquartered? | Anhui Huaren Health is headquartered in China. |
| How many employees does Anhui Huaren Health have? | As of today, Anhui Huaren Health has 6K+ employees. |
| Is Anhui Huaren Health publicy listed? | Yes, Anhui Huaren Health is a public company listed on SHE. |
| What is the stock symbol of Anhui Huaren Health? | Anhui Huaren Health trades under 301408 ticker. |
| When did Anhui Huaren Health go public? | Anhui Huaren Health went public in 2023. |
| Who are competitors of Anhui Huaren Health? | Similar companies to Anhui Huaren Health include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Anhui Huaren Health? | Anhui Huaren Health's current market cap is $673M |
| Is Anhui Huaren Health profitable? | Yes, Anhui Huaren Health is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
